NEW YORK, Nov. 17, 2014 /PRNewswire/ -- Anterios, Inc., a privately held medical dermatology and aesthetic medicine biopharmaceutical company, announced today that it has hired Fabian Tenenbaum to serve as its Chief Financial Officer and Chief Business Officer. Mr. Tenenbaum brings a diverse skill set to the position, including both deep financial management expertise, as well as executive management and business development skills in the medical aesthetic and consumer healthcare arenas.
"We're thrilled to expand the operational and strategic capabilities of the management team with the addition of Mr. Tenenbaum, "commented CEO and Founder of Anterios, Inc., Dr. Jon Edelson. "Mr. Tenenbaum's range of experience will be valuable as we grow the company both through advancing the development of our topical botulinum product candidate ANT-1207 for the indications of hyperhidrosis (excessive sweating), acne and facial wrinkles and advancing our next generation injectable botulinum product candidate AI-09."
Prior to joining Anterios, Mr. Tenenbaum was the CEO of Iluminage Beauty, a Unilever joint-venture company, which develops and sells energy-based aesthetic medical devices. From 2011 to 2013, he co-founded and then served as CEO of Syneron Beauty until the company was spun-off to Unilever. From 2007 to 2011, Mr. Tenenbaum was Executive Vice President and CFO for Syneron-Candela, a leading global aesthetic medical device company, where he oversaw financial management and investor relations, M&A strategy, global commercial initiatives and partnerships, and its international subsidiaries. Prior to Syneron, Mr. Tenenbaum held executive leadership positions with several life-science companies including Radiancy and Sunlight Medical. He also served on the Board of Directors for Rakuto Bio Technologies Ltd. and Fluorinex Active Ltd. Mr. Tenenbaum holds an MBA (as a Dean's List honoree) from Columbia University and a Bachelor in Medicine (summa cum laude) from the Faculty of Medicine at Ben Gurion University. Mr. Tenenbaum assumed his role at Anterios, Inc. this month.
About Anterios, Inc.
Anterios, Inc. ("Anterios") is a privately held clinical stage biopharmaceutical company that is developing next generation botulinum-based prescription products for medical dermatology and aesthetic medicine. Anterios has developed the proprietary NDS platform technology that enables local, targeted delivery of botulinum toxin and other macromolecules across the skin without needles or other invasive treatments that can be destructive to the skin. NDS also enables the formulation of macromolecules as ready-to-use liquid injectable products. In the future, Anterios plans to develop additional dermatology products to topically deliver active ingredients other than botulinum, as well as formulate additional injectable products that require deeper delivery. More information can be found at www.anteriosinc.com.
SOURCE Anterios, Inc.